AI Portfolio Summary
In 2025 Q4, Spruce Street Capital LP maintained a portfolio of 27 distinct positions. The most significant new addition to the portfolio was CIDARA THERAPEUTICS , which now represents 16.95% of the total fund value.
Total Positions
27
Quarter
2025 Q4
Top Holding
CDTX (17.0%)
Top 10 Concentration
70.8%
Turnover Rate
23.4%
Sector HHI
0.18
Items per page:
Showing 1-27 of 27
| Stock | History | Sector / Type | Port % | Prev % | Rank / Prev | Conviction | Change | % Change | Influence | Shares | Mkt Value | Avg Cost | Price Held | 1st Owned | Source | Source Date | Date Reported |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
CDTX
CIDARA THERAPEU...
|
Unknown | 16.95% | — |
#1
Prev: #—
|
9.5 | 232,269 | no change |
NEW
|
232,269 | $51,305,899 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
RLAY
RELAY THERAPEUT...
|
Healthcare | 8.34% | — |
#2
Prev: #—
|
8.3 | 2,984,125 | no change |
NEW
|
2,984,125 | $25,245,698 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
LBRX
LB PHARMACEUTIC...
|
Healthcare | 7.40% | — |
#3
Prev: #—
|
7.5 | 1,005,593 | no change |
NEW
|
1,005,593 | $22,384,500 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
RLMD
RELMADA THERAPE...
|
Healthcare | 6.52% | — |
#4
Prev: #—
|
6.6 | 4,086,181 | no change |
NEW
|
4,086,181 | $19,736,254 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
PCVX
VAXCYTE INC
|
Healthcare | 6.10% | — |
#5
Prev: #—
|
6.4 | 400,360 | no change |
NEW
|
400,360 | $18,472,610 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
KNSA
KINIKSA PHARMAC...
|
Healthcare | 5.93% | — |
#6
Prev: #—
|
5.9 | 434,982 | no change |
NEW
|
434,982 | $17,943,008 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
EYPT
EYEPOINT INC
|
Healthcare | 5.93% | — |
#7
Prev: #—
|
5.9 | 981,543 | no change |
NEW
|
981,543 | $17,932,791 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
SVRA
SAVARA INC
|
Healthcare | 4.80% | — |
#8
Prev: #—
|
5.4 | 2,411,093 | no change |
NEW
|
2,411,093 | $14,538,891 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ERAS
ERASCA INC
|
Healthcare | 4.78% | — |
#9
Prev: #—
|
5.4 | 3,889,632 | no change |
NEW
|
3,889,632 | $14,469,431 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
DNTH
DIANTHUS THERAP...
|
Healthcare | 4.05% | — |
#10
Prev: #—
|
5.1 | 297,437 | no change |
NEW
|
297,437 | $12,257,379 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
SRZN
SURROZEN INC
|
Healthcare | 3.23% | — |
#11
Prev: #—
|
4.8 | 432,040 | no change |
NEW
|
432,040 | $9,764,104 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
OCUL
OCULAR THERAPEU...
|
Healthcare | 3.14% | — |
#12
Prev: #—
|
4.8 | 783,999 | no change |
NEW
|
783,999 | $9,517,748 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
SABS
SAB BIOTHERAPEU...
|
Healthcare | 2.72% | — |
#13
Prev: #—
|
4.6 | 2,198,502 | no change |
NEW
|
2,198,502 | $8,222,397 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
IKT
INHIBIKASE THER...
|
Healthcare | 2.43% | — |
#14
Prev: #—
|
4.5 | 3,581,603 | no change |
NEW
|
3,581,603 | $7,342,286 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ELVN
ENLIVEN THERAPE...
|
Healthcare | 2.27% | — |
#15
Prev: #—
|
4.4 | 446,084 | no change |
NEW
|
446,084 | $6,869,694 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
NERV
MINERVA NEUROSC...
|
Healthcare | 2.20% | — |
#16
Prev: #—
|
4.4 | 1,655,500 | no change |
NEW
|
1,655,500 | $6,655,110 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ABVX
ABIVAX SA
|
Healthcare | 2.19% | — |
#17
Prev: #—
|
4.4 | 49,119 | no change |
NEW
|
49,119 | $6,623,943 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
CYBN
CYBIN INC
|
Unknown | 2.08% | — |
#18
Prev: #—
|
4.3 | 770,000 | no change |
NEW
|
770,000 | $6,298,600 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
KALV
KALVISTA PHARMA...
|
Healthcare | 2.07% | — |
#19
Prev: #—
|
4.3 | 387,968 | no change |
NEW
|
387,968 | $6,265,683 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ENTA
ENANTA PHARMACE...
|
Healthcare | 2.03% | — |
#20
Prev: #—
|
4.3 | 389,687 | no change |
NEW
|
389,687 | $6,145,364 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ANRO
ALTO NEUROSCIEN...
|
Healthcare | 1.31% | — |
#21
Prev: #—
|
4.0 | 222,844 | no change |
NEW
|
222,844 | $3,966,623 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
LONA
ATHIRA PHARMA I...
|
Healthcare | 0.98% | — |
#22
Prev: #—
|
3.9 | 393,701 | no change |
NEW
|
393,701 | $2,980,317 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
CNTA
CENTESSA PHARMA...
|
Healthcare | 0.64% | — |
#23
Prev: #—
|
3.8 | 77,997 | no change |
NEW
|
77,997 | $1,950,705 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ALEC
ALECTOR INC
|
Healthcare | 0.58% | — |
#24
Prev: #—
|
3.7 | 1,117,986 | no change |
NEW
|
1,117,986 | $1,744,058 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
LXEO
LEXEO THERAPEUT...
|
Healthcare | 0.57% | — |
#25
Prev: #—
|
3.7 | 175,000 | no change |
NEW
|
175,000 | $1,737,750 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
IPSC
CENTURY THERAPE...
|
Healthcare | 0.47% | — |
#26
Prev: #—
|
3.7 | 1,421,532 | no change |
NEW
|
1,421,532 | $1,414,140 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
STRO
SUTRO BIOPHARMA...
|
Healthcare | 0.29% | — |
#27
Prev: #—
|
3.6 | 75,594 | no change |
NEW
|
75,594 | $874,623 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) |
Showing 1-27 of 27 holdings